Health AI Central
Share:
Peer-Reviewed Publication
J Med Chem2026June 17, 2026Journal Article

Synthetic Approaches to the New Drugs Approved During 2024.

Scott P France1, Erick A Lindsey2, Emma L McInturff3, Simon Berritt4, Andrew C Flick5, Sarah Fink6, Tony S Gibson7, Kaitlyn Gray3, Aran K Hubbell3, Amber M Johnson3, Yiyang Liu1, Subham Mahapatra4, Rebecca B Watson3, Zhiyao Zhou1
1Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
2Neomorph, Department of Chemistry, San Diego, California 92121, United States.
3Chemical Research and Development, Pfizer, Inc., Groton, Connecticut 06340, United States.
4Medicine Design, Pfizer, Inc., Groton, Connecticut 06340, United States.
5Genesis Therapeutics, San Diego, California 92121, United States.
6Topo Therapeutics, Watertown, Massachusetts 02472, United States.
7Ferdia Therapeutics LLC, San Diego, California 92130, United States.
PubMed DOI

Abstract

In 2024, thirty-nine new small molecule drugs were approved worldwide. A brief introduction to each new drug is followed by the synthetic details that highlight the most scalable routes available at the time of publication in patents or primary literature. Structural complexity varies widely across the drugs that are included in the review, as do the methods of synthesis used to access these new d…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.